These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 29602760)

  • 1. Preventing the development and progression of diabetic kidney disease: Where do we stand?
    Zagkotsis G; Markou M; Paschou E; Papanikolaou P; Sabanis N
    Diabetes Metab Syndr; 2018 Jul; 12(4):585-590. PubMed ID: 29602760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update of pathophysiology and management of diabetic kidney disease.
    Lin YC; Chang YH; Yang SY; Wu KD; Chu TS
    J Formos Med Assoc; 2018 Aug; 117(8):662-675. PubMed ID: 29486908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of diabetic nephropathy: Recent progress and future perspective.
    Ahmad J
    Diabetes Metab Syndr; 2015; 9(4):343-58. PubMed ID: 25845297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological Targeting of Mitochondria in Diabetic Kidney Disease.
    Cleveland KH; Schnellmann RG
    Pharmacol Rev; 2023 Mar; 75(2):250-262. PubMed ID: 36781216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renin-Angiotensin-Aldosterone system blockade in diabetic kidney disease: A critical and contrarian point of view.
    Elrggal ME; Ahmed SM; El Nahas M
    Saudi J Kidney Dis Transpl; 2016; 27(6):1103-1113. PubMed ID: 27900954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Diabetic Kidney Disease With Hypertension Control and Renin Angiotensin System Inhibition.
    Patney V; Chaudhary K; Whaley-Connell A
    Adv Chronic Kidney Dis; 2018 Mar; 25(2):158-165. PubMed ID: 29580580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease.
    Górriz JL; Navarro-González JF; Ortiz A; Vergara A; Nuñez J; Jacobs-Cachá C; Martínez-Castelao A; Soler MJ
    Nephrol Dial Transplant; 2020 Jan; 35(Suppl 1):i13-i23. PubMed ID: 32003834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urine matrix metalloproteinase-7 and risk of kidney disease progression and mortality in type 2 diabetes.
    Afkarian M; Zelnick LR; Ruzinski J; Kestenbaum B; Himmelfarb J; de Boer IH; Mehrotra R
    J Diabetes Complications; 2015; 29(8):1024-31. PubMed ID: 26412030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current concepts in the management of diabetic nephropathy.
    Waanders F; Visser FW; Gans RO
    Neth J Med; 2013 Nov; 71(9):448-58. PubMed ID: 24218418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms for Cardiorenal Protection of SGLT-2 Inhibitors.
    Georgianos PI; Vaios V; Dounousi E; Salmas M; Eleftheriadis T; Liakopoulos V
    Curr Pharm Des; 2021; 27(8):1043-1050. PubMed ID: 33463454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on role of direct renin inhibitor in diabetic kidney disease.
    Dhakarwal P; Agrawal V; Kumar A; Goli KM; Agrawal V
    Ren Fail; 2014 Jul; 36(6):963-9. PubMed ID: 24678880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel biomarkers for prognosticating diabetic kidney disease progression.
    Swaminathan SM; Rao IR; Shenoy SV; Prabhu AR; Mohan PB; Rangaswamy D; Bhojaraja MV; Nagri SK; Nagaraju SP
    Int Urol Nephrol; 2023 Apr; 55(4):913-928. PubMed ID: 36271990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current developments in renal failure in diabetic patients].
    Lindenmeyer M
    Praxis (Bern 1994); 2015 Feb; 104(4):187-95. PubMed ID: 25669223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cardiovascular protection of diabetic patient with chronic renal disease and particular case of end-stage renal disease in elderly patients].
    Zaoui P; Hannedouche T; Combe C
    Nephrol Ther; 2017 Jun; 13(6S):6S16-6S24. PubMed ID: 29463395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic kidney disease: a report from an ADA Consensus Conference.
    Tuttle KR; Bakris GL; Bilous RW; Chiang JL; de Boer IH; Goldstein-Fuchs J; Hirsch IB; Kalantar-Zadeh K; Narva AS; Navaneethan SD; Neumiller JJ; Patel UD; Ratner RE; Whaley-Connell AT; Molitch ME
    Am J Kidney Dis; 2014 Oct; 64(4):510-33. PubMed ID: 25257325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review on pathophysiology and treatment of diabetic kidney disease.
    Satirapoj B
    J Med Assoc Thai; 2010 Nov; 93 Suppl 6():S228-41. PubMed ID: 21280541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.